Cancer Genetics, Inc. to Host Conference Call to Discuss Strategic and Business Rationale of vivoPharm Acquisition
Conference call scheduled for Tuesday, August 22, 2017- 8:30 AM Eastern
RUTHERFORD, N.J. and LOS ANGELES, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (The Company and CGI), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will host an investor and analyst call and webcast on Tuesday, August 22, 2017 at 8:30 am Eastern. CGI will discuss the strategy and business rationale of the recent transformative and accretive acquisition of vivoPharm.
CGI’s acquisition of vivoPharm, announced on August 14, 2017, will significantly strengthen the Company's position as a leader for oncology discovery and early phase clinical development and testing for biotechnology and pharmaceutical companies. With over a decade of experience in delivering a wide range of discovery and preclinical services to support drug development, target validation and biomarker analysis, vivoPharm has supported over 200 IND submissions for innovative therapies, with a significant focus on immuno-oncology.
Hosted by CGI's CEO and President, Mr. Panna Sharma, the call will introduce investors and analysts to new members of the CGI team, including Dr. Ralf Brandt, former CEO and Managing Director of vivoPharm, who now serves as the President of Discovery & Early Development Services at CGI.
Mr. Sharma will also provide insight into both operational and customer synergies that will result from the integration of vivoPharm, as well as the long-term strategy for growth. Additional details will also be provided on vivoPharm’s specialized tumor and disease models, toxicology and pharmacology services, biomarker analysis and animal imaging capabilities that are expected to provide CGI new opportunities to deepen its relationships with existing biopharma customers through additional discovery and downstream molecular work, while bolstering the Company’s previously announced initiative aimed at early-phase drug repurposing and drug rescue programs.
The call details are noted in the table below.
|CONFERENCE CALL & WEBCAST|
|Tuesday, August 22, 2017, 8:30 am Eastern Time|
|Replays – Available through September 5, 2017|
ABOUT CANCER GENETICS
Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.
Forward Looking Statements:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. tests and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.
Investor Relations Contact: Richard Moyer Cameron Associates 535 Fifth Ave., New York, NY 10017 Tel: 212-554-5466 Email: email@example.com
Released August 16, 2017